86 related articles for article (PubMed ID: 27489860)
1. Ibrutinib repurposing: from B-cell malignancies to solid tumors.
Massó-Vallés D; Jauset T; Soucek L
Oncoscience; 2016; 3(5-6):147-8. PubMed ID: 27489860
[No Abstract] [Full Text] [Related]
2. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
3. Development of BTK inhibitors for the treatment of B-cell malignancies.
Kim HO
Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
[TBL] [Abstract][Full Text] [Related]
4. Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.
Campbell R; Chong G; Hawkes EA
J Clin Med; 2018 Mar; 7(4):. PubMed ID: 29561760
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.
George B; Chowdhury SM; Hart A; Sircar A; Singh SK; Nath UK; Mamgain M; Singhal NK; Sehgal L; Jain N
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455989
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.
Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Siddiqui N; Al-Harbi MM; Attia SM; Bakheet SA
Pharmacol Res; 2019 Oct; 148():104441. PubMed ID: 31505252
[TBL] [Abstract][Full Text] [Related]
7. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
Kuo HP; Ezell SA; Hsieh S; Schweighofer KJ; Cheung LW; Wu S; Apatira M; Sirisawad M; Eckert K; Liang Y; Hsu J; Chen CT; Beaupre D; Chang BY
Am J Cancer Res; 2016; 6(11):2489-2501. PubMed ID: 27904766
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
Bose P; Gandhi VV; Keating MJ
Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1381-1392. PubMed ID: 27686109
[TBL] [Abstract][Full Text] [Related]
9. Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.
Barbarino V; Henschke S; Blakemore SJ; Izquierdo E; Michalik M; Nickel N; Möllenkotte I; Vorholt D; Müller L; Brinker R; Fedorchenko O; Mikhael N; Seeger-Nukpezah T; Hallek M; Pallasch CP
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824276
[TBL] [Abstract][Full Text] [Related]
10. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.
Li Y; Bouchlaka MN; Wolff J; Grindle KM; Lu L; Qian S; Zhong X; Pflum N; Jobin P; Kahl BS; Eickhoff JC; Wuerzberger-Davis SM; Miyamoto S; Thomas CJ; Yang DT; Capitini CM; Rui L
Oncogene; 2016 Dec; 35(48):6223-6234. PubMed ID: 27157620
[TBL] [Abstract][Full Text] [Related]
11. Repurposing ibrutinib: therapeutic effects and implications for translational approaches in Alzheimer's disease.
Lee HJ; Hoe HS
Neural Regen Res; 2023 Oct; 18(10):2194-2195. PubMed ID: 37056133
[No Abstract] [Full Text] [Related]
12. Targeting Btk with ibrutinib inhibit gastric carcinoma cells growth.
Wang JD; Chen XY; Ji KW; Tao F
Am J Transl Res; 2016; 8(7):3003-12. PubMed ID: 27508020
[TBL] [Abstract][Full Text] [Related]
13. Second-generation inhibitors of Bruton tyrosine kinase.
Wu J; Liu C; Tsui ST; Liu D
J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
[TBL] [Abstract][Full Text] [Related]
14. Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
Johnson AR; Kohli PB; Katewa A; Gogol E; Belmont LD; Choy R; Penuel E; Burton L; Eigenbrot C; Yu C; Ortwine DF; Bowman K; Franke Y; Tam C; Estevez A; Mortara K; Wu J; Li H; Lin M; Bergeron P; Crawford JJ; Young WB
ACS Chem Biol; 2016 Oct; 11(10):2897-2907. PubMed ID: 27571029
[TBL] [Abstract][Full Text] [Related]
15. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
[TBL] [Abstract][Full Text] [Related]
16. Role of myeloid-derived suppressor cells in tumor recurrence.
Cole K; Al-Kadhimi Z; Talmadge JE
Cancer Metastasis Rev; 2023 Mar; 42(1):113-142. PubMed ID: 36640224
[TBL] [Abstract][Full Text] [Related]
17. Preparation and Optimization of Ibrutinib-Loaded Nanoliposomes Using Response Surface Methodology.
Ashar F; Hani U; Osmani RAM; Kazim SM; Selvamuthukumar S
Polymers (Basel); 2022 Sep; 14(18):. PubMed ID: 36146030
[TBL] [Abstract][Full Text] [Related]
18. Glutamine Metabolism in Cancer.
Li T; Copeland C; Le A
Adv Exp Med Biol; 2021; 1311():17-38. PubMed ID: 34014532
[TBL] [Abstract][Full Text] [Related]
19. Targeting Solid Tumors With BTK Inhibitors.
Uckun FM; Venkatachalam T
Front Cell Dev Biol; 2021; 9():650414. PubMed ID: 33937249
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
